cardiopulmonary resuscitation, comatose, status epilepticus, cardiac arrest
Conditions
Brief summary
The primary outcome measure will be functional recovery expressed as the score on the extended Glasgow Outcome Scale (eGOS) at six months after cardiac arrest. eGOS scores at six months are obtained by a standardized telephone interview conducted by an independent investigator, who is masked to treatment allocation and EEG pattern.
Detailed description
Cost-effectiveness analysis outcomes are Quality Adjusted Life Years (QALYs), costs, Incremental Cost Effectiveness Ratio (ICER), incremental cost-effectiveness plane, and incremental cost-effectiveness acceptability curve.
Interventions
DRUGPropofol 10 mg/ml MCT/LCT Fresenius emulsie voor injectie of infusie
DRUGDiazepam CF 5 mg/ml
DRUGoplossing voor injectie
DRUGEsketiv 25 mg/ml
DRUGLorazepam Macure 4 mg/ml oplossing voor injectie
DRUGDepakine i.v. 400
DRUGpoeder voor injectievloeistof 400 mg
DRUGVimpat 10 mg/ml solution for infusion
DRUGMidazolam Eugia 1 mg/ml
Sponsors
Universiteit Twente
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The primary outcome measure will be functional recovery expressed as the score on the extended Glasgow Outcome Scale (eGOS) at six months after cardiac arrest. eGOS scores at six months are obtained by a standardized telephone interview conducted by an independent investigator, who is masked to treatment allocation and EEG pattern. | — |
Secondary
| Measure | Time frame |
|---|---|
| Cost-effectiveness analysis outcomes are Quality Adjusted Life Years (QALYs), costs, Incremental Cost Effectiveness Ratio (ICER), incremental cost-effectiveness plane, and incremental cost-effectiveness acceptability curve. | — |
Countries
Belgium, Netherlands
Outcome results
None listed